Patentability Of Biotech Inventions Remain Uncertain As Supreme Court Declines Case
This article was originally published in The Gray Sheet
Executive Summary
Multiple health-care stakeholders had asked the high court to take up the case of Sequenom v. Ariosa to clarify the patentability of a biotech patent. Now the Federal Circuit's interpretation that, firms say, leaves too many innovations unprotected continues to hold sway.